Today, with more than 40 cancer immunotherapy indications and over 2,000 clinical trials with cancer immunotherapies, the challenges and issues around patient selection, patient access and side effect management for the community cancer team have grown even more complex. ACCC recognizes and understands these complexities and the rapidly changing IO landscape and strives leading the exchange of solutions to proactively address the operational, optimization, research and educational challenges associated with cancer immunotherapies for the community cancer care team.
An ACCC Institute, ICLIO is the only initiative to prepare all members of the multidisciplinary cancer care team for the complex implementation of immuno-oncology in the community setting. ICLIO provides robust resources for staying up to date on this rapidly evolving field, as well as practical real-world information on effectively integrating immunotherapy into practice.
To view all that ICLIO offers and learn about the newest initiatives, visit the ICLIO website at accc-iclio.org.
Two ACCC member programs are participating in "Overcoming Obstacles in Integrating Immunotherapies for Cancer in the Community Setting," a quality improvement research study. Learn more and view the study design.
Peer-to-peer learning focused on practical “how to’s” for integrating immunotherapy into practice in the community setting with a focus on physical space considerations, workflow, staffing, patient education, and lessons learned.
The rapid pace of new approvals and indications in immunotherapy for cancer requires ongoing education to understand the spectrum of immune-related adverse events (irAEs) and how to effectively manage your patients’ irAEs using a multidisciplinary approach.